




Innovative Therapy Implementation (ITI) Summit

-  Rosewood Hotel, Abu Dhabi
-  25th May 2024
-  9:00 AM - 4:00 PM



Welcome Message

Dear Esteemed Guests and Speakers,

I am honoured to welcome you to the first Innovative Therapy Implementation (ITI) Summit in Abu Dhabi. Together, we are setting the stage for a landmark discussion on the integration of ground-breaking therapies within the UAE's healthcare framework.

During this summit, we will delve into critical areas including the challenges of adopting new therapies, specifically in the realm of cancer, and the successes we have achieved through strong stakeholder collaboration.

Your contributions as leaders, experts, and innovators are vital to shaping a resilient healthcare system that embraces cutting-edge practices. Together, we will explore challenges, share insights, and collaborate on solutions that enhance patient care and uphold the UAE's position as a beacon of innovation on the global stage.

I look forward to your participation and to the rich discussions that will spark from this gathering.

Professor Shahrukh Hashmi
Chair, ITI Summit



Professor Shahrukh Hashmi
Director of Research, DOH

Agenda

Time	Session	Description	Speaker(s) / Notes
09:50- 10:00	Conference Opening		Prof. Shahrukh Hashmi, Director of Research, DOH
Overview of Current Situation and Challenges for Introducing Innovative Therapies in UAE Session Chair: Dr. Kayane Mheidly, Consultant Haematology			
10:00 - 10:20	Introduction to Past, Present, and Future of Cancer Medicines Implementation in UAE	Overview of Reimbursement Approaches in Different Emirates and Future Prospects	Dr. Sara Al Dallal, President of the Emirates Health Economics Society
10:20 - 10:40	Role of Research in Early Access of Treatments		Prof. Shahrukh Hashmi, Director of Research, DOH
10:40 - 11:00	Precision Medicine Future: Access Challenges and Solutions		Dr. Shaikha Almazrouei, Chairperson of UAE Stem Cell Society
Q&A and Panel Discussion: 11:00 – 11:30			
Coffee and Networking: 11:30 – 11:50			
Innovative Haematology Therapies in Practice Session Chair: Dr. Husni Al Hateeti, Chairman Haematology and Oncology, SSMC			
11:50 - 12:10	Dubai: Experience in Implementing and Reimbursement of Innovative Cancer Therapies		Prof. Mohamed Fargahly, DHA
12:10 - 12:30	Abu Dhabi: Practical Examples of How Innovative Treatments Changed the Treatment Algorithm in Haematology <ul style="list-style-type: none">• Chemo-Free Regimens• BiTES• ADCs	Clinician’s Perspective	Dr. Panayotis Kaloyannidis, Haematologist, Burjeel Medical City
12:30 – 12:45	<ul style="list-style-type: none">• Oral Chemotherapy• Case-Studies Focused Session	Pharmacist’s Perspective	Dr. Lina Wahba, Tawam Dr. Islam Elkonaissi, Clinical Pharmacist
Q&A and Panel Discussion: 12:45 – 13:00			
Lunch and Networking 13:00 – 13:45			


Agenda

Collaboration and Engagment Session Chair: Dr. Marleine Bejjani, Director of Pharmacy, SSMC			
13:45 - 14:05	Case Studies for Inpatient DRG Calculations		Mr. Lojain Moussa, Financial Counselling and Authorization Manager, SSMC Mrs. Sally Al Kabaz, Senior Financial Counselling, SSMC
Q&A Session: 14:05 - 14:15			
Panel Discussion Session – Presenting Challenges and Exploring Solutions Session Chair: Prof. Shahrukh Hashmi, Director of Research, DOH			
14:15 - 15:25	Panel Discussion	Roundtable Discussion <ul style="list-style-type: none"> • Dr. Adel Al Assy, M42 • Mr. James Pearce, DOH • Dr. Sawsan Al Madhi, Advocacy Advisor, CEO • Dr. Bassel Jallad, Consultant Haematology • Dr. Mazin Gadir, Digital Health • Dr. Mohamed Mostafa, CEO PDC-CRO • Mr. Pedro Matos Rosa, GM J&J GCC • Dr. Ravi Sharma, Director of Pharmacy, Burjeel 	Senior Leaders Session – Challenges and Solutions
15:25 - 15:30	Closing Remarks Prof. Shahrukh Hashmi		

Overview

Journey of Innovative Therapy Implementation

It is a three-phase process required for successful integration of new treatments into healthcare systems. Phase one, marked in **GREEN**, involves initial planning, assessing diagnostic capabilities, and evaluating the impact of new treatments on existing management pathways. The second phase, highlighted in **ORANGE**, addresses the accessibility of these therapies, including considerations for clinical trials, budgeting, and insurance coverage. The final phase, in **PURPLE**, details the practical implementation steps such as integrating IT systems, developing clinical guidelines, and mobilizing necessary equipment and specialized teams. Additionally, potential risks such as lead time, insurance coverage adjustments, and changes in guidelines or leadership are identified, emphasizing the complexity and multifaceted nature of healthcare innovation.



FACULTY



Prof. Shahrukh Hashmi
Director of Research, DOH



Dr. Sara Al Dallal
*President of the Emirates
Health Economics Society*



Dr. Shaikha Almazrouei
*Chairperson of UAE Stem
Cell Society*



Prof. Mohamed Fargahly
*Consultant and Director of
Health Insurance Policies*



Dr. Sawzan Al Madhi
*Advocacy Advisor, Eastern
Mediterranean NCD
Alliance; CEO and Founder,
AlignnEfficient Health
Consultancies CO LLC*



Mr. James Pearce
*Division Director, Healthcare
Payers Planning, DOH*



Dr. Husni Al Hateeti
*Chairman Haematology and
Oncology SSMC*



Dr. Marleine Bejjani
Director of Pharmacy, SSMC



Dr. Mazin Gadir
*Director of Strategic
Partnership, IQVIA*



Dr. Islam Elkonaissi
Clinical Pharmacist



Dr. Adel Al Assy
*Senior Manager - Pharma
Category - Supply Chain, M42*



Dr. Kayane Mheidly
*Consultant Haematology,
SSMC*



Dr. Mohamed Mostafa,
*Chief Executive Officer PDC-
CRO*



Dr. Panayotis Kaloyannidis
*Haematologist, Burjeel
Medical City*




Mr. Lojain Moussa
Revenue Cycle Manager



Dr. Lina Wahba
*Head of Clinical Pharmacy and
Oncology Clinical Pharmacist,
Tawam Hospital*



Dr. Bassel Jallad
*Medical Oncology &
Haematology, CCAD*



Mrs. Sally Al Kabaz
Revenue Cycle Supervisor



Mr. Pedro Matos Rosa
*General Manager Johnson &
Johnson Innovative Medicines
Gulf*



Dr. Ravi Sharma
*Director of Pharmacy,
Burjeel*

Organizing Committee



PROF. SHAहरुKH HASHMI
DIRECTOR OF RESEARCH, DOH
CHAIR, ITI SUMMIT



DR. ISLAM ELKONAISSI
CLINICAL PHARMACIST



MS. NASTARAN SHEKARY
Clinical Trials Specialist



DR. KAYANE MHEIDLY
CONSULTANT
HAEMATOLOGY, SSMC

Innovative Therapy Implementation (ITI) Summit

Abu Dhabi 2024

Supported By

GOLD



SILVER



Organized By





Contact Us



Website

Seroevents.com



HQ address

Dubai, UAE



E-mail

info@seroevents.com